To support the scientific community in combating antimicrobial resistance (AMR), ATCC offers a comprehensive and expanding collection of clinically relevant, drug-resistant strains. These strains are backed by source information, genotypic data, and susceptibility profiles, providing essential tools that support the global effort to combat superbugs and emerging resistance mechanisms. 

• Develop and validate rapid diagnostic assays
• Screen and evaluate novel antibiotics and therapeutic agents
• Enhance sterility assurance protocols
• Advance resistance mechanism research

Whether you're working on hospital-acquired infections, emerging superbugs, or global surveillance initiatives, ATCC provides the critical biological materials needed to accelerate your research and innovation.

Explore the portfolio  Learn more about AMR  Contact us

Antimicrobial resistance (AMR) is one of the most urgent public health threats of our time. According to the Centers for Disease Control and Prevention (CDC), more than 1.27 million people die annually as a direct result of drug-resistant infections, with nearly 5 million deaths associated with AMR globally. If current trends continue, up to 10 million deaths could be lost annually by 2050 due to antibiotic-resistant infections (de Kraker MEA, et al.). The rise of multidrug-resistant organisms poses a serious challenge to modern medicine.

Despite ongoing efforts to develop new antibiotics and strengthen antimicrobial stewardship, novel resistance mechanisms are emerging at an alarming pace. In this evolving landscape, early detection and access to well-characterized microbial strains are more critical than ever. As a trusted global resource, ATCC provides authenticated antimicrobial-resistant strains, enabling researchers to accelerate the development of diagnostics, therapeutics, and surveillance tools that combat the growing threat of drug resistance.